Cynthia Comella, MD

Long-Term Treatment With Valbenazine 40 mg Once-Daily in Adults With Tardive Dyskinesia

Background: Valbenazine, a novel and highly selective VMAT2 inhibitor, is approved for the treatment of TD in adults. Data from two long-term studies (KINECT 3 [K3], KINECT 4 [K4]) and a ...

Carlos Singer , MD;

Leslie Lundt , MD;

Craig Chepke , MD, DFAPA;

Khodayar Farahmand , PharmD;

Cynthia Comella , MD;

11/22/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8 ⁠–⁠ November 10

November 8

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Cynthia Comella, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products